{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:57:41Z","timestamp":1787673461086,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Scientific Research Fund at Helwan University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s43440-025-00787-6","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T07:37:33Z","timestamp":1758872253000},"page":"1741-1750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Palbociclib in endocrine-resistant metastatic breast cancer patients: gene polymorphism- based study"],"prefix":"10.1007","volume":"77","author":[{"given":"Abdel-Hameed","family":"Ibrahim Mohamed Ebid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1131-7594","authenticated-orcid":false,"given":"Yasmine","family":"Magdy Fahim Genina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Haffez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"Hassanien Ahmed Hakam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loay","family":"Mohamed Hassan Kassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mohamed Mohamed Abdelmotaleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"3","key":"787_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"key":"787_CR2","doi-asserted-by":"crossref","unstructured":"Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025:1\u20139.","DOI":"10.1038\/s41591-025-03502-3"},{"key":"787_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10549-019-05176-1","volume":"176","author":"L Varella","year":"2019","unstructured":"Varella L, Eziokwu AS, Jia X, Kruse M, Moore HC, Budd GT, et al. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with Palbociclib and endocrine therapy. Breast Cancer Res Treat. 2019;176:429\u201334.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"787_CR4","first-page":"e37","volume":"33","author":"Miller TWJASoCOEB","year":"2013","unstructured":"Miller TWJASoCOEB. Endocrine resistance: what do we know? Am Soc Clin Oncol. 2013;33(1):e37\u201342.","journal-title":"Am Soc Clin Oncol"},{"issue":"2","key":"787_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.6004\/jnccn.2018.7094","volume":"17","author":"J Xi","year":"2019","unstructured":"Xi J, Oza A, Thomas S, Ademuyiwa F, Weilbaecher K, Suresh R, et al. Retrospective analysis of treatment patterns and effectiveness of Palbociclib and subsequent regimens in metastatic breast cancer. J Natl Compr Canc Netw. 2019;17(2):141\u20137.","journal-title":"J Natl Compr Canc Netw"},{"key":"787_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective Cyclin D kinase 4\/6 inhibitor, preferentially inhibits the proliferation of luminal Estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:1\u201313.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"787_CR7","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3390\/cancers17040693","volume":"17","author":"M Guliyev","year":"2025","unstructured":"Guliyev M, G\u00fcren AK, \u00d6zge E, \u00c7olak R, Majidova N, Alkan \u015een G, et al. The impact of progesterone receptor status on survival outcomes in metastatic breast cancer patients treated with First-Line CDK4\/6 inhibitors. Cancers (Basel). 2025;17(4):693.","journal-title":"Cancers (Basel)"},{"key":"787_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2017.05.016","volume":"35","author":"R Costa","year":"2017","unstructured":"Costa R, Costa R, Talamantes SM, Helenowski I, Peterson J, Kaplan J, et al. Meta-analysis of selected toxicity endpoints of CDK4\/6 inhibitors: palbociclib and ribociclib. Breast. 2017;35:1\u20137.","journal-title":"Breast"},{"issue":"4","key":"787_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/17425255.2021.1876661","volume":"17","author":"H Bruckmueller","year":"2021","unstructured":"Bruckmueller H, Cascorbi, IJEoodm. toxicology. ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding? Expert Opin Drug Metab Toxicol. 2021;17(4):369\u201396.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"787_CR10","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1023\/B:PHAM.0000029276.21063.0b","volume":"21","author":"C Pauli-Magnus","year":"2004","unstructured":"Pauli-Magnus C, Kroetz DLJP. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res. 2004;21:904\u201313.","journal-title":"Pharm Res"},{"issue":"22","key":"787_CR11","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2013college of American pathologists guideline update. J Clin Oncol. 2023;41(22):3867\u201372.","journal-title":"J Clin Oncol"},{"issue":"12","key":"787_CR12","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol. 2020;38(12):1346\u201366.","journal-title":"J Clin Oncol"},{"issue":"9","key":"787_CR13","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Th\u00fcrlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24(9):2206\u201323.","journal-title":"Ann Oncol"},{"issue":"4","key":"787_CR14","doi-asserted-by":"publisher","first-page":"e455","DOI":"10.1093\/oncolo\/oyad304","volume":"29","author":"J-I Lai","year":"2024","unstructured":"Lai J-I, Kuo T-H, Huang K-J, Chai LMX, Lee M-H, Liu C-Y, et al. Clinical and genotypic insights into higher prevalence of palbociclib associated neutropenia in Asian patients. Oncologist. 2024;29(4):e455\u201366.","journal-title":"Oncologist"},{"key":"787_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, De Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1\u2014update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132\u20137.","journal-title":"Eur J Cancer"},{"key":"787_CR16","doi-asserted-by":"publisher","first-page":"115479","DOI":"10.1016\/j.biopha.2023.115479","volume":"167","author":"E Peruzzi","year":"2023","unstructured":"Peruzzi E, Gerratana L, Montico M, Posocco B, Corsetti S, Bartoletti M, et al. Association of ADME gene polymorphisms on toxicity to CDK4\/6 inhibitors in patients with HR\u2009+\u2009HER2-metastatic breast cancer. Biomed Pharmacother. 2023;167:115479.","journal-title":"Biomed Pharmacother"},{"issue":"17","key":"787_CR17","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.3390\/cancers13174455","volume":"13","author":"MGHS Davey","year":"2021","unstructured":"Davey MGHS, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers (Basel). 2021;13(17):4455.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"787_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-024-07352-4","volume":"207","author":"E Rewcastle","year":"2024","unstructured":"Rewcastle E, Skaland I, Gudlaugsson E, Fykse SK, Baak JP, Janssen EAJBCR, et al. The Ki67 dilemma: investigating prognostic cut-offs and reproducibility for automated Ki67 scoring in breast cancer. Breast Cancer Res Treat. 2024;207(1):1\u201312.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"787_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.21037\/atm-21-1340","volume":"9","author":"X Shao","year":"2021","unstructured":"Shao X, Zheng Y, Cao W, Shen X, Li G, Chen J, et al. Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study. Annals Translational Med. 2021;9(8):707.","journal-title":"Annals Translational Med"},{"key":"787_CR20","doi-asserted-by":"publisher","first-page":"S363","DOI":"10.1016\/j.annonc.2023.09.608","volume":"34","author":"LN Berlanga","year":"2023","unstructured":"Berlanga LN, Teso B, Paco PF, De la Haba Rodriguez J, Armenta A, Mora F, et al. 432P Ki67 and progesterone receptor status could be predict sensitivity to cyclin-dependent kinase inhibitor. Ann Oncol. 2023;34:S363\u20134.","journal-title":"Ann Oncol"},{"issue":"12","key":"787_CR21","first-page":"662","volume":"75","author":"M Kimura","year":"2020","unstructured":"Kimura M, Usami E, Yoshimura T. Association between severe neutropenia and progression-free survival in patients with advanced or recurrent breast cancer treated with palbociclib. Die Pharmazie-An Int J Pharm Sci. 2020;75(12):662\u20135.","journal-title":"Die Pharmazie-An Int J Pharm Sci"},{"issue":"5","key":"787_CR22","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1111\/cas.13556","volume":"109","author":"T Kosaka","year":"2018","unstructured":"Kosaka T, Shinojima T, Morita S, Oya MJC. Prognostic significance of grade 3\/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel. Cancer Sci. 2018;109(5):1570\u20135.","journal-title":"Cancer Sci"},{"issue":"10","key":"787_CR23","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1634\/theoncologist.2016-0097","volume":"21","author":"S Verma","year":"2016","unstructured":"Verma S, Bartlett CH, Schnell P, DeMichele AM, Loi S, Ro J, et al. Palbociclib in combination with fulvestrant in women with hormone receptor-positive\/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3). Oncologist. 2016;21(10):1165\u201375.","journal-title":"Oncologist"},{"issue":"12","key":"787_CR24","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1634\/theoncologist.2019-0019","volume":"24","author":"V Di\u00e9ras","year":"2019","unstructured":"Di\u00e9ras V, Harbeck N, Joy AA, Gelmon K, Ettl J, Verma S, et al. Palbociclib with letrozole in postmenopausal women with ER+\/HER2\u2009\u2013\u2009advanced breast cancer: hematologic safety analysis of the randomized PALOMA-2 trial. Oncologist. 2019;24(12):1514\u201325.","journal-title":"Oncologist"},{"issue":"7","key":"787_CR25","doi-asserted-by":"publisher","first-page":"e1143","DOI":"10.1002\/onco.13811","volume":"26","author":"H Iwata","year":"2021","unstructured":"Iwata H, Umeyama Y, Liu Y, Zhang Z, Schnell P, Mori Y, et al. Evaluation of the association of polymorphisms with palbociclib-induced neutropenia: pharmacogenetic analysis of PALOMA-2\/-3. Oncologist. 2021;26(7):e1143\u201355.","journal-title":"Oncologist"},{"issue":"3","key":"787_CR26","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10549-021-06215-6","volume":"188","author":"KB Kristensen","year":"2021","unstructured":"Kristensen KB, Thomsen IMN, Berg T, Kodahl AR, Jensen AB. Dose modifications of ribociclib and endocrine therapy for treatment of ER\u2009+\u2009HER2\u2009\u2013\u2009metastatic breast cancer. Breast Cancer Res Treat. 2021;188(3):799\u2013809.","journal-title":"Breast Cancer Res Treat"},{"issue":"15suppl","key":"787_CR27","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1200\/JCO.2021.39.15_suppl.1027","volume":"39","author":"L Palmero","year":"2021","unstructured":"Palmero L, Mazzeo R, Buriolla S, Allegri L, Bortot L, Franzoni A, et al. Refining neutropenia risk assessment in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6i) for metastatic breast cancer (MBC) through a cell-free DNA workflow (cfDNA). J Clin Oncol. 2021;39(15suppl):1027.","journal-title":"J Clin Oncol"},{"issue":"1","key":"787_CR28","first-page":"616","volume":"17","author":"N Arima","year":"2019","unstructured":"Arima N, Nishimura R, Osako T, Okumura Y, Nakano M, Fujisue M, et al. Ki\u201367 index value and progesterone receptor status can predict prognosis and suitable treatment in node\u2013negative breast cancer patients with estrogen receptor\u2013positive and HER2\u2013negative tumors. Oncol Lett. 2019;17(1):616\u201322.","journal-title":"Oncol Lett"},{"issue":"15suppl","key":"787_CR29","doi-asserted-by":"publisher","first-page":"e14080","DOI":"10.1200\/jco.2010.28.15_suppl.e14080","volume":"28","author":"PG Alfonso","year":"2010","unstructured":"Alfonso PG, Alvarez S, Mu\u00f1oz A, Riesco M, Gonzalez-Haba E, L\u00f3pez-Lillo C, et al. Association of single nucleotide polymorphisms (SNP) in the ABCB1 gene with neutropenia and diarrhea protection in capecitabine and 5-fluorouracil-treated colorectal cancer patients, respectively. J Clin Oncol. 2010;28(15suppl):e14080\u2013e.","journal-title":"J Clin Oncol"},{"issue":"17","key":"787_CR30","doi-asserted-by":"publisher","first-page":"6350","DOI":"10.3390\/ijms21176350","volume":"21","author":"R Roncato","year":"2020","unstructured":"Roncato R, Angelini J, Pani A, Cecchin E, Sartore-Bianchi A, Siena S, et al. CDK4\/6 inhibitors in breast cancer treatment: potential interactions with drug, gene, and pathophysiological conditions. Int J Mol Sci. 2020;21(17):6350.","journal-title":"Int J Mol Sci"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00787-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00787-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00787-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:01:38Z","timestamp":1764115298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00787-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["787"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00787-6","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by both the Institutional Review Board (IRB) of the Medical Professions Development Sector, Ministry of Health, Cairo, Egypt\n                      (\n                      Ethical Committee Approval No. 4-2024\/4) and the ethical committee at Faculty of Pharmacy, Helwan University, Cairo, Egypt (Ethical Committee Approval No. 01H2024). The study protocol was conducted in accordance with Good Clinical Practice Principles and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was signed by each patient to be enrolled in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}